Your browser doesn't support javascript.
loading
One science-driven approach for the regulatory implementation of alternative methods: A multi-sector perspective.
Dal Negro, Gianni; Eskes, Chantra; Belz, Susanne; Bertein, Caroline; Chlebus, Magda; Corvaro, Marco; Corvi, Raffaella; Dhalluin, Stephane; Halder, Marlies; Harvey, Jim; Hermann, Martina; Hoffmann-Dörr, Simone; Kilian, Karin; Lambrigts, Denis; Laroche, Charles; Louhimies, Susanna; Mahony, Catherine; Manou, Irene; McNamee, Pauline; Prieto, Pilar; Reid, Kirsty; Roggen, Erwin; Schutte, Katrin; Stirling, Catrina; Uhlrich, Sylvie; Weissenhorn, Renate; Whelan, Maurice.
Afiliação
  • Dal Negro G; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom.
  • Eskes C; SeCAM Services and Consultation on Alternative Methods, Via Campagnora 1, 6983, Magliaso, Switzerland. Electronic address: chantra.eskes@secam-ce.eu.
  • Belz S; European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy.
  • Bertein C; A.I.S.E, Boulevard du Souverain 164, 1160, Brussels, Belgium.
  • Chlebus M; European Federation of Pharmaceutical Industries and Associations (EFPIA), Rue du Trône 108, 1050, Brussels, Belgium.
  • Corvaro M; ECPA - the European Crop Protection Association, 6 Avenue E. Van Nieuwenhuyse, 1160, Brussels, Belgium.
  • Corvi R; European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy.
  • Dhalluin S; L'Oréal Research & Innovation, 9 rue Pierre Dreyfus, 92110, Clichy, France.
  • Halder M; European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy.
  • Harvey J; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom.
  • Hermann M; Henkel AG & Co. KGaA, Henkelstr. 67, 40589, Duesseldorf, Germany.
  • Hoffmann-Dörr S; Henkel AG & Co. KGaA, Henkelstr. 67, 40589, Duesseldorf, Germany.
  • Kilian K; European Commission, Directorate General for the Environment (DG ENV), Brussels, Belgium.
  • Lambrigts D; GlaxoSmithKline Vaccines, 20 Avenue Fleming, 1300, Wavre, Belgium.
  • Laroche C; European Partnership for Alternative Approaches to Animal Testing (EPAA), Av. Herrmann-Debroux 40, 1160, Brussels, Belgium.
  • Louhimies S; European Commission, Directorate General for the Environment (DG ENV), Brussels, Belgium.
  • Mahony C; The Procter & Gamble Company, Whitehall Lane, Egham, Surrey TW20 9NW, United Kingdom.
  • Manou I; European Partnership for Alternative Approaches to Animal Testing (EPAA), Av. Herrmann-Debroux 40, 1160, Brussels, Belgium.
  • McNamee P; The Procter & Gamble Company, Whitehall Lane, Egham, Surrey TW20 9NW, United Kingdom.
  • Prieto P; European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy.
  • Reid K; European Federation of Pharmaceutical Industries and Associations (EFPIA), Rue du Trône 108, 1050, Brussels, Belgium.
  • Roggen E; 3Rs Management and Consulting, Asavænget 14, 2800, Kongens Lyngby, Denmark.
  • Schutte K; European Commission, Directorate General for the Environment (DG ENV), Brussels, Belgium.
  • Stirling C; Zoetis Ltd, Kent, United Kingdom.
  • Uhlrich S; Sanofi Pasteur, 1541 Av. Marcel Merieux, 69280, Marcy l'Etoile, France.
  • Weissenhorn R; European Commission, Directorate General for Internal Market, Industry, Enterpreneurship and SME, Brussels, Belgium.
  • Whelan M; European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy.
Regul Toxicol Pharmacol ; 99: 33-49, 2018 Nov.
Article em En | MEDLINE | ID: mdl-30098372
ABSTRACT
EU regulations call for the use of alternative methods to animal testing. During the last decade, an increasing number of alternative approaches have been formally adopted. In parallel, new 3Rs-relevant technologies and mechanistic approaches have increasingly contributed to hazard identification and risk assessment evolution. In this changing landscape, an EPAA meeting reviewed the challenges that different industry sectors face in the implementation of alternative methods following a science-driven approach. Although clear progress was acknowledged in animal testing reduction and refinement thanks to an integration of scientifically robust approaches, the following challenges were identified i) further characterization of toxicity pathways; ii) development of assays covering current scientific gaps, iii) better characterization of links between in vitro readouts and outcome in the target species; iv) better definition of alternative method applicability domains, and v) appropriate implementation of the available approaches. For areas having regulatory adopted alternative methods (e.g., vaccine batch testing), harmonised acceptance across geographical regions was considered critical for broader application. Overall, the main constraints to the application of non-animal alternatives are the still existing gaps in scientific knowledge and technological limitations. The science-driven identification of most appropriate methods is key for furthering a multi-sectorial decrease in animal testing.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Indústrias / Alternativas aos Testes com Animais Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Implementation_research Limite: Animals / Humans País/Região como assunto: Europa Idioma: En Revista: Regul Toxicol Pharmacol Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Indústrias / Alternativas aos Testes com Animais Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Implementation_research Limite: Animals / Humans País/Região como assunto: Europa Idioma: En Revista: Regul Toxicol Pharmacol Ano de publicação: 2018 Tipo de documento: Article